Epilepsy

The director of the Epilepsy Program at Children’s Hospital of Philadelphia spoke about the long-awaited advancement brought on by cannabidiol for Dravet syndrome.

This novel dosage form of diazepam had comparable times to maximal concentration in both 2-hour and 4-hour timeframes.

The section chief of pediatric neurology at Nationwide Children’s Hospital and an associate professor of clinical pediatrics and neurology at The Ohio State University College of Medicine spoke about what the findings mean for patients.

The recently approved therapy remained generally well tolerated and improvements in overall condition in Subject/Caregiver Global Impression of Change scores.

Neurology News Network for the week of November 10, 2018.

Cognitive complaints remain a major issue for patients with epilepsy, leading the epileptologist at the University of Pennsylvania to share her insight into addressing them.

The clinical professor in pediatric neurology and director of regional neurology services at Children's Hospital Colorado shared her thoughts on why epilepsy is the perfect paradigm to implement telemedicine.

This is the first oral film formulation of clobazam approved, highlighting the challenge of medication administration in patients with LGS, who often struggle due to physical, behavioral, or cognitive impacts.

The epileptologist discussed this challenge, and shared her thoughts on how to maintain this communication.

The approval and immediate launch of the product in both tablet and oral suspension offer a generic alternative to Onfi.

The assistant professor of neurology at the University of Pennsylvania discussed the complication of cognitive issues faced by patients with epilepsy, and how these are being addressed in the clinic.

Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.

The medical director of digital health at Cleveland Clinic spoke about the role telehealth plays in a society where technology constantly advances and changes.

Because automobiles are such an important aspect of our culture, driving restriction is an enormous problem for many of the 65 million individuals with epilepsy worldwide and their families.

The pediatric neurologist discussed the importance of the recent FDA approval of perampanel in pediatrics with partial-onset seizures with or without secondarily generalized seizures.

Digital medicine is used to increase access for rural and underserved areas, allowing for the delivery of patient care, patient monitoring and specialist consultations.

Safety data for pediatrics was consistent with the safety profile in adult populations, without the need for weight-based dosing.

GW Pharmaceuticals stated that it plans to bring the drug to market in the United States in the next 6 weeks.

A pilot study has identified a potential link between obstructive sleep apnea and a higher risk of sudden unexpected death in epilepsy.

The associate chief of clinical pediatric neurology, director of the pediatric neurophysiology lab, and director at the Adolescent Epilepsy Center at UCLA spoke about therapeutic options for pediatric epilepsy.

M. Scott Perry, MD, spoke about the industry's excitement surrounding the current treatment landscape for pediatric epilepsy.

The Medical Director of Neurology and Justin Neurosciences Center at Cook Children's Medical Center spoke about the importance of staying up-to-date and informed about this rapidly changing space.

Neurology News Network for the week of September 15, 2018.

The director of the Epilepsy Program at the Banner University Medical Center spoke about the importance of interaction between general neurology and epileptologists.

Jason Lerner MD, discussed the recently opened Adolescent Epilepsy Center at UCLA, a clinic that offers comprehensive care for teens with epilepsy.

The idea of marijuana as a panacea for neurologic conditions has come into play, leading to a need for clarification about the use of CBD for these conditions.

Study findings revealed that AED clearance significantly changes by the first trimester for levetiracetam and by the second trimester for oxcarbazepine and topiramate.

Xenon Pharmaceuticals announced the expansion of its ion channel pipeline as a result of feedback from the FDA.

The director of the Epilepsy Program at the Banner University Medical Center spoke about the needs in patient populations with epilepsy.

Previously, in a 5-year phase I-II trial, the rAAV vector serotype rh.10 showed promising safety data.